Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Vivosim Lab Inc (VIVS)

Vivosim Lab Inc (VIVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services GlobeNewswire - Tue Jul 21, 7:05AM CDT

SAN DIEGO, July 21, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety,...

VIVS : 0.4189 (-6.91%)
VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor GlobeNewswire - Thu Jul 16, 7:30AM CDT

SAN DIEGO, July 16, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for...

VIVS : 0.4189 (-6.91%)
VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027 GlobeNewswire - Wed Jul 15, 7:05AM CDT

SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models...

VIVS : 0.4189 (-6.91%)
VivoSim: Fiscal Q4 Earnings Snapshot AP - Tue Jul 14, 4:12PM CDT

VivoSim: Fiscal Q4 Earnings Snapshot

VIVS : 0.4189 (-6.91%)
VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting GlobeNewswire - Mon Jun 29, 7:05AM CDT

SAN DIEGO, June 29, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety,...

VIVS : 0.4189 (-6.91%)
VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing GlobeNewswire - Tue Apr 28, 7:05AM CDT

SAN DIEGO, April 28, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety,...

VIVS : 0.4189 (-6.91%)
VivoSim Announces Pricing of up to a $4 Million Public Offering GlobeNewswire - Wed Apr 1, 7:05AM CDT

SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS), (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical...

VIVS : 0.4189 (-6.91%)
VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs GlobeNewswire - Tue Mar 24, 7:05AM CDT

SAN DIEGO, March 24, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety,...

VIVS : 0.4189 (-6.91%)
VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales GlobeNewswire - Tue Mar 3, 7:05AM CST

SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety,...

VIVS : 0.4189 (-6.91%)
VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego GlobeNewswire - Wed Feb 11, 7:05AM CST

SAN DIEGO, Feb. 11, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety,...

VIVS : 0.4189 (-6.91%)

Barchart Exclusives

Texas Instruments vs. Qualcomm: One Pays Out 94% of Earnings. The Better Dividend Chip Stock Is Clear. Barchart - Fri Jul 24, 6:00PM CDT
Texas Instruments and Qualcomm offer different paths to AI growth and dividend income, but which chip stock gives investors the better setup? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.